Scholarlink

<p>There is a lack of biomarkers in pleural fluid that can reliably differentiate benign from malignant pleural effusions. This study was done to study the role of pleural fluid calprotectin levels as a biomarker of malignant effusions and its utility in predicting pleurodesis success in such cases. Sixty three patients with undiagnosed pleural effusion were prospectively enrolled who underwent diagnostic thoracocentesis. Calprotectin levels were measured with the help of a quantitative ELISA kit (Krishgen Human calprotectin GENLISA). Pleural fluid routine biochemistry, ferritin, IL-6, LDH levels, cytology and microbiological investigations were also done. Fifteen patients of malignant pleural effusion underwent pleurodesis by intrapleural instillation of Injection Doxycycline (500&#xa0;mg) after informed consent. Students t test, ROC(Receiver operating characteristic curve) were used in analysis. Thirty one (49.2%) patients had malignant effusion while the rest 32 (50.8%) had benign effusion. Pleural fluid calprotectin reliably differentiated malignant from benign pleural effusion with an AUC(area under curve) of 0.85. It could also differentiate malignant from tubercular effusion with an AUC of 0.91. Ten out of 31 malignant effusion cases (66%) underwent successful pleurodesis. AUC (area under the curve) for calprotectin was 0.95 with a cut off &gt; 332.3&#xa0;ng/ml for predicting pleurodesis success. Pleural fluid calprotectin has the potential to become a veritable biomarker for malignant pleural effusion and a predictor for pleurodesis success in these subset of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pleural Fluid Calprotectin Levels in Benign and Malignant Pleural Effusions and Its Significance in Predicting Success of Pleurodesis in Malignant Pleural Effusions

  • 期刊论文

  • 发表日期：

    2025年1月13日

查看全文
  • Amartya Chakraborti,
  • Nishant Kumar Chauhan,
  • Naveen Dutt,
  • Mithu Banerjee,
  • Ravisekhar Gadepalli,
  • Deepak Vedant,
  • M. K. Garg,
  • Gopal Durgeshwar,
  • Hariharan Iyer

摘要

There is a lack of biomarkers in pleural fluid that can reliably differentiate benign from malignant pleural effusions. This study was done to study the role of pleural fluid calprotectin levels as a biomarker of malignant effusions and its utility in predicting pleurodesis success in such cases. Sixty three patients with undiagnosed pleural effusion were prospectively enrolled who underwent diagnostic thoracocentesis. Calprotectin levels were measured with the help of a quantitative ELISA kit (Krishgen Human calprotectin GENLISA). Pleural fluid routine biochemistry, ferritin, IL-6, LDH levels, cytology and microbiological investigations were also done. Fifteen patients of malignant pleural effusion underwent pleurodesis by intrapleural instillation of Injection Doxycycline (500 mg) after informed consent. Students t test, ROC(Receiver operating characteristic curve) were used in analysis. Thirty one (49.2%) patients had malignant effusion while the rest 32 (50.8%) had benign effusion. Pleural fluid calprotectin reliably differentiated malignant from benign pleural effusion with an AUC(area under curve) of 0.85. It could also differentiate malignant from tubercular effusion with an AUC of 0.91. Ten out of 31 malignant effusion cases (66%) underwent successful pleurodesis. AUC (area under the curve) for calprotectin was 0.95 with a cut off > 332.3 ng/ml for predicting pleurodesis success. Pleural fluid calprotectin has the potential to become a veritable biomarker for malignant pleural effusion and a predictor for pleurodesis success in these subset of patients.